Edgewise Therapeutics, Inc. Common Stock (EWTX) Stock
NASDAQ · EWTX
Key stats
- Market cap
- $5.21B
- Price / Earnings ratio
- 5.0x
- EPS (TTM)
- $9.24
- Volume
- Loading
- 52-week high
- $48.78
- 52-week low
- $18.10
Source: third-party data provider, as of November 13, 2026
Compare with EWTX
Recent news

Reuters
Edgewise shares slip after heart-disease drug trial data disappoints investors
EWTXJune 16, 2026
Reuters
Edgewise shares slip after heart-disease drug trial data disappoints investors
EWTX

Investors Business Daily
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
EWTXJune 16, 2026
Investors Business Daily
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
EWTX

Zacks Investment Research
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTXJune 2, 2026
Zacks Investment Research
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTX

Investors Business Daily
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang
EWTXJune 1, 2026
Investors Business Daily
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang
EWTX
Technical indicators
- RSI 14
- 67.66
- MACD 12/26/9
- 1.44
- EMA 9 of MACD
- 0.27
- MACD histogram
- 1.16
- SMA 50
- $41.17
- Price above SMA 50
- EMA 50
- $41.05
- Price above EMA 50
- SMA 200
- $36.84
- Price above SMA 200
- EMA 200
- $35.97
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Strong Sell0
Sell0
Hold0
Buy4
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
663M438M219M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-167.8M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Reuters
Edgewise shares slip after heart-disease drug trial data disappoints investors
EWTXJune 16, 2026
Reuters
Edgewise shares slip after heart-disease drug trial data disappoints investors
EWTX

Investors Business Daily
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
EWTXJune 16, 2026
Investors Business Daily
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
EWTX

Zacks Investment Research
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTXJune 2, 2026
Zacks Investment Research
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTX

Investors Business Daily
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang
EWTXJune 1, 2026
Investors Business Daily
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang
EWTX

Reuters
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
EWTXJune 1, 2026
Reuters
Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
EWTX

Stocktwits
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?
EWTXMay 5, 2026
Stocktwits
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?
EWTX

The Motley Fool
Why Edgewise Therapeutics Stock Topped the Market on Tuesday
EWTXMarch 17, 2026
The Motley Fool
Why Edgewise Therapeutics Stock Topped the Market on Tuesday
EWTX

Stocktwits
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites
EWTXFebruary 18, 2026
Stocktwits
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites
EWTX

The Motley Fool
Why Edgewise Therapeutics Stock Crushed the Market on Monday
EWTXFebruary 10, 2026
The Motley Fool
Why Edgewise Therapeutics Stock Crushed the Market on Monday
EWTX

The Motley Fool
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits
EWTXDecember 29, 2025
The Motley Fool
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits
EWTX
About Edgewise Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees127
CEODr. Kevin Koch Ph.D.
IPO DateMar 26, 2021
HeadquartersBoulder, CO
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Kevin Koch Ph.D. | President, CEO & Director | 1960 |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Chairman | 1960 |
| Mr. Michael P. Nofi | Chief Financial Officer | 1971 |
| Dr. Behrad Derakhshan Ph.D. | Chief Operating Officer | 1980 |
| Dr. Badreddin Edris Ph.D. | Co-Founder & Independent Director | 1987 |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer & Director | 1970 |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer | 1957 |
| Mr. John R. Moore J.D. | General Counsel | 1964 |
| Dr. Aylin Tugcu | Senior Vice President of Cardiovascular Clinical Development & Medical Affairs | — |
Fundamentals
Valuation
Price-to-book value3.12
Profitability
Return on Equity130.00%
Return on Assets121.00%
EBITDA$1.17B
Trading
Average volume1,721,864
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 67.66
- MACD 12/26/9
- 1.44
- EMA 9 of MACD
- 0.27
- MACD histogram
- 1.16
- SMA 50
- $41.17
- Price above SMA 50
- EMA 50
- $41.05
- Price above EMA 50
- SMA 200
- $36.84
- Price above SMA 200
- EMA 200
- $35.97
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $51.00
- Average
- $56.00
- High
- $60.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.3 | -5.6 | ||||||||||
| 2022 | -17.7 | -14.0 | -13.5 | -17.7 | -25.0 | +37.5 | +19.7 | +13.5 | -6.5 | -2.2 | -5.2 | +4.2 |
| 2023 | +16.4 | -7.0 | -30.4 | +29.7 | +5.9 | -22.4 | -3.3 | -11.3 | -11.2 | +10.9 | -5.7 | +76.7 |
| 2024 | +62.1 | -14.9 | +9.3 | -0.4 | -9.9 | +3.4 | -12.1 | +11.9 | +49.3 | +22.9 | -2.9 | -15.3 |
| 2025 | +3.7 | -7.2 | -13.8 | -18.5 | -14.4 | -10.8 | +11.2 | +0.3 | +9.2 | +18.4 | +44.9 | -1.8 |
| 2026 | +18.5 | +5.4 | +6.1 | -6.6 | +11.6 | +0.9 | -1.8 | +8.8 | -3.9 | -3.9 | +24.8 |
Compare stocks
Market cap
$5.21B
-
-
-
Price / Earnings ratio
5.00
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,721,864
-
-
-
Earnings per share
$9.24
-
-
-



